4d Pharma buoyed by Texas cancer treatment partnership
7th Jan 2019 08:20
(Sharecast News) - 4d Pharma's shares enjoyed a boost on Monday after entering a collaboration with a specialist cancer unit at the University of Texas.
Read more4d Pharma losses little changed as trials begin
28th Sep 2018 08:29
(Sharecast News) - First-half losses grew slightly at live biotherapeutics developer 4d Pharma as first-half research and development expenses jumped ahead of two of its major treatment candidates receiving clearance for clinical trials.
Read morePositive top-line results for 4D Pharma's Thetanix
24th Sep 2018 14:19
(Sharecast News) - Biotherapeutics company 4D Pharma announced positive top-line results for its Phase 1b study of 'Thetanix' in paediatric patients with Crohn's disease on Monday.
Read more4D Pharma begins Thetanix phase 1 clinical trial
22nd Aug 2016 11:57
(ShareCast News) - Pharmaceutical company 4D pharma has begun dosing in a phase 1 clinical trial with Thetanix for the treatment of Paediatric Crohn's disease (PCD). PCD is a rare chronic inflammatory bowel disease that is caused by the malfunction of the immune system leading to inflammation, or sw
Read more4D Pharma announces encouraging first clinical trial of Blautix
19th Jul 2016 10:00
(ShareCast News) - 4D Pharma announced a positive response from its Blautix treatment for irritable bowel syndrome (IBS) in a phase 1 clinical trial. The trial was a first in man study and, as previously reported by the company, Blautix was found to be both safe and well tolerated and achieved the p
Read more4D Pharma irritable bowel treatment proves safe in clinical trial
23rd May 2016 12:49
(ShareCast News) - Early clinical trials of 4D Pharma's treatment for irritable bowel syndrome (IBS) have successfully shown Blautix to be safe and well tolerated. Blautix, which contains live bacteria, like all 4D's products, was delivered orally to 56 healthy volunteers and IBS patients. Data fro
Read more4D Pharma gobbles up Biomar production assets
8th Apr 2016 16:17
(ShareCast News) - 4D Pharma announced a major acquisition on Friday, gobbling up the production assets of Spanish-based contract research organisation Biomar. The AIM-traded pharmaceutical company, which focuses on the development of live biotherapeutics, said Biomar had been working as an outsourc
Read moreGood news, and some not-so-good news from 4D pharma
26th Feb 2016 15:49
(ShareCast News) - 4D pharma brought some good news and some bad news to the market on Friday, over its trials of irritable bowel syndrome (IBS) treatment Blautix, and it paediatric Crohn's disease treatment Thetanix. The AIM-traded pharmaceutical company, with a focus on the development of live bio
Read more4D Pharma expands research with Tuscana acquisition
10th Feb 2016 15:12
(ShareCast News) - 4D Pharma expanded its research capabilities on Wednesday, acquiring university-based startup Tuscana Health Limited. The AIM traded pharmaceutical company, focused on the development of live biotherapeutics, said Tuscana - based at University College Cork - was founded to investi
Read moreFTSE 250 movers: Miners drag index down, Synthomer spikes higher
11th Aug 2015 14:15
(ShareCast News) - The FTSE 250 index was by late on Tuesday afternoon giving up some of the gains made late the day before, as commodities-focused stocks were hit by China's devaluation and corporate news received mixed reviews. By 1540 BST the index was down 0.47% at 17,677.29 points, with Vedanta
Read more4D Pharma posts "exciting" development results from MicroRx
16th Jun 2015 08:33
Pharmaceutical company 4D Pharma said it had made significant progress in its research efforts using its proprietary platform MicroRx. The Manchester-based outfit was able to identify candidates for the treatment of severe asthma, allergic asthma and rheumatoid arthritis. The group also identified
Read more4d Pharma posts losses of £2.38m in maiden results
5th Jun 2015 11:04
Pharmaceutical company 4d Pharma has reported losses of £2.38m in its maiden set of full-year results. Basic losses per share totalled 4.81p. 4d, which uses selected bacteria to develop treatments, said that during the period its cash, cash equivalents, deposits and short-term investments increased
Read more4D pharma progresses with IBS and Crohn's treatments
2nd Sep 2014 10:21
4D pharma has announced that its treatments for Irritable Bowel Syndrome (IBS) and Paediatric Crohn's Disease (PCD) are expected to enter clinical studies in the second quarter of 2015. The studies, which will be focused on evaluating safety and tolerability of the products as well as some clinica
Read more4d pharma increases stake in GT Biologics to nearly 84%
4th Jun 2014 07:53
4d pharma, an AIM-listed pharmaceutical company focused on new therapeutic areas, has added an additional 37.5% to its stake in GT Biologics taking its current holding to around 83.5%. The £1.22m consideration was satisfied by the issue of 699,500 new 4d shares at 175p each, reflecting their avera
Read more